Subjects in each category, * persons-years at risk, § Wald Test, ± Adjusted for age, sex and HIV infection

Crude rates and adjusted incidence rate ratios for TB incidence and death, in ITT, m-ITT (excluding culture positive cases at baseline) and per-protocol population.

These associations are derived from Poisson models, with county and year as the panel levels. Model 1 is comprised of precipitation as the single independent variable, Model 2 is comprised of temperature as the single independent variable, and Model 3 is comprised of hydrogeographic area as the single independent variable.1Precipitation is the total monthly precipitation accumulation in centimeters from May through October.2Temperature is the monthly-weighted seasonal cumulative temperature in degrees Celsius.

Objective To present the epidemiological characteristics of incidence and mortality of ischemic and hemorrhagic stroke in national cardiovascular disease surveillance areas from 2015 to 2019.Methods Data of stroke incidence and mortality from 2015 to 2019 were collected from the China Registry of Cardiovascular Events (China RACE)，which was established in 2014, covering 100 counties (cities, districts) in 31 provinces in China. The ratio of ischemic to hemorrhagic stroke incidence rates were calculated, and the subtype-specific mortality to incidence ratio (M/I) were provided and compared between subtypes. The Joinpoint model was used to analyze the annual trend incidence rates (annual percentage changes, APC). The age-standardized incidence rate (ASIR) was calculated using the Seventh National Census data as the standard population.Results From 2015 to 2019, the crude incidence rate (CIR) of ischemic stroke increased by 15.61% (APC=3.54%, Ptrend < 0.01), resulting in a relative ratio of incidence rate reaching 4.35:1 against hemorrhagic stroke. And the crude incidence rate of ischemic stroke rural areas increased 24.05% (APC=5.69%, Ptrend < 0.01), accompanied with more rapid increasing presented in male (APC=4.00%, Ptrend < 0.01) than in female (APC=3.01%, Ptrend < 0.01). Meanwhile, the overall ASIR of hemorrhagic stroke decreased by 20.99% (APC= -5.59%, Ptrend < 0.05) , with 29.38% reduction (APC=-8.10%, Ptrend < 0.01) counted in rural areas, as well as more slow decline showed in males (APC=-5.07%, Ptrend < 0.05) than in females (APC= -6.33%, Ptrend < 0.05). Moreover, the residents aged 45-49 years presented an increasing trend in the CIR of ischemic stroke (Ptrend < 0.05) from 2015 to 2019, paralleled with a decreasing trend in hemorrhagic stroke (Ptrend < 0.05) among those aged 70-74, 80-84 and ≥85 years. Except for those < 35 years old, the incidence ratio of ischemic to hemorrhagic stroke increased with age in 2019. From 2015 to 2019, the overall relative ratio of M/I (RR) for ischemic to hemorrhagic stroke was 4.2:1, which was lower in urban than in rural areas (3.8 vs 4.3). The largest gap between urban and rural areas was detected in the 55-59 age group (6.8 vs 9.3).Conclusions Ischemic and hemorrhagic stroke incidence in the monitoring areas was remarkably severe, and the geographic diversity and age-specific divergence became more complicated by stroke subtypes. More precise and comprehensive policies are urgently required in China.

Sex-specific annual incidence and prevalence per 100,000 population and sex risk ratio of MS in Mazandaran, Iran.

The crude prevalence rate of diabetes is defined as the ratio of respondents that are 18 years or older who have ever been told by a health professional that they had diabetes (other than during pregnancy) over the total number of respondents in the study (excluding those who refused to answer, had a missing answer, or answered “don’t know/not sure”).Prevalence data are derived from Behavioral Risk Factor Surveillance System (BRFSS) (numerator) and population estimates from the U.S. Census Bureau (denominator).The 500 Cities Project seeks to provide city- and census tract-level small area estimates for chronic disease risk factors, health outcomes, and clinical preventive service use for the largest 500 cities in the United States.Data source: CDC (Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion)Date: 2015

Mortality and morbidity experience data from 2010 through 2013 on group insurance policies

Crude TB incidence and death rates and adjusted incidence rate ratios: stratified analysis on m-ITT population.

*Adjusted for birth year, birth order (1, 2+), maternal age (≤20, 21–34, ≥35), smoking in pregnancy (yes/no), maternal, history of epilepsy, and maternal history of diabetes or preeclampsia/eclampsia.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases among people who received additional or booster doses were reported from 31 jurisdictions; 30 jurisdictions also reported data on deaths among people who received one or more additional or booster dose; 28 jurisdictions reported cases among people who received two or more additional or booster doses; and 26 jurisdictions reported deaths among people who received two or more additional or booster doses. This list will be updated as more jurisdictions participate. Incidence rate estimates: Weekly age-specific incidence rates by vaccination status were calculated as the number of cases or deaths divided by the number of people vaccinated with a primary series, overall or with/without a booster dose (cumulative) or unvaccinated (obtained by subtracting the cumulative number of people vaccinated with a primary series and partially vaccinated people from the 2019 U.S. intercensal population estimates) and multiplied by 100,000. Overall incidence rates were age-standardized using the 2000 U.S. Census standard population. To estimate population counts for ages 6 months through 1 year, half of the single-year population counts for ages 0 through 1 year were used. All rates are plotted by positive specimen collection date to reflect when incident infections occurred. For the primary series analysis, age-standardized rates include ages 12 years and older from April 4, 2021 through December 4, 2021, ages 5 years and older from December 5, 2021 through July 30, 2022 and ages 6 months and older from July 31, 2022 onwards. For the booster dose analysis, age-standardized rates include ages 18 years and older from September 19, 2021 through December 25, 2021, ages 12 years and older from December 26, 2021, and ages 5 years and older from June 5, 2022 onwards. Small numbers could contribute to less precision when calculating death rates among some groups. Continuity correction: A continuity correction has been applied to the denominators by capping the percent population coverage at 95%. To do this, we assumed that at least 5% of each age group would always be unvaccinated in each jurisdiction. Adding this correction ensures that there is always a reasonable denominator for the unvaccinated population that would prevent incidence and death rates from growing unrealistically large due to potential overestimates of vaccination coverage. Incidence rate ratios (IRRs): IRRs for the past one month were calculated by dividing the average weekly incidence rates among unvaccinated people by that among people vaccinated with a primary series either overall or with a booster dose. Publications: Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1284–1290. Johnson AG, Amin AB, Ali AR, et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021. MMWR Morb Mortal Wkly Rep 2022;71:132–138. Johnson AG, Linde L, Ali AR, et al. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination — 24 U.S. Jurisdictions, October 3, 2021–December 24, 2022. MMWR Morb Mortal Wkly Rep 2023;72:145–152. Johnson AG, Linde L, Payne AB, et al. Notes from the Field: Comparison of COVID-19 Mortality Rates Among Adults Aged ≥65 Years Who Were Unvaccinated and Those Who Received a Bivalent Booster Dose Within the Preceding 6 Months — 20 U.S. Jurisdictions, September 18, 2022–April 1, 2023. MMWR Morb Mortal Wkly Rep 2023;72:667–669.

Geographic and time distribution of COVID-19 cases, deaths, cumulative incidence rate and case fatality ratio by ADM0 and EW. Also contains data on hospitalization and ICU occupancy.

Field Name

Type

Description

OBJECTID

ObjectID

SHP Object Unique Identifier

ISO3_CODE

String

ISO 3166 Country code

PLACE

String

ISO 3166 Country name

DATE_YEAR

Integer

Year in integer format

DATA_DATE

String

Date in character format

DATE_WEEK_NUM

Integer

Epidemiological Week (EW)

CUM_RECO

Integer

Cumulative recovered cases

WHO_SUBREGION

String

Subregion within the Americas: - North America, - Central America, - South America, - Caribbean and Atlantic Ocean Islands

NEW_RECO

Integer

New recovered cases compared with the previous period (day or week)

REAL_DATE

Date

Date in date format (YYY/MM/DD)

TOTAL_CASES

Integer

Total cumulative cases by area from start

TOTAL_DEATHS

Integer

Total cumulative deaths by area from start

NEW_TOTAL_CASES

Integer

New total cases for the measurement latest period (day or week)

NEW_TOTAL_DEATHS

Integer

New total deaths compared with the previous period (day or week)

HOSP

Integer

Hospitalization total patients

RATE

Double

Cumulative Incidence Rate

CFR

Double

Case Fatality Ratio (%) Crude

HOSP_OCCUP

Double

Hospital bed occupancy

ICU

Integer

Intensive Care Unit total patients

ICU_OCCUP

Double

Intensive Care Unit bed occupancy

Cumulative COVID-19 cases, deaths and rates by ADM1 / Latest

Field Name

Type

Description

WHO_SUBREGION

String

Subregion within the Americas: - North America, - Central America, - South America, - Caribbean and Atlantic Ocean Islands

ADM1_ISOCODE

String

ISO 3166 Adm1 code

EW

Integer

Epidemiological Week (EW)

DATA_DATE

String

Date in character format

PLACE

String

ISO 3166 Country name

ISO3_CODE

String

ISO 3166 Country code

ADM1_NAME

String

ISO 3166 Adm1 name

OBJECTID

ObjectID

SHP Object Unique Identifier

RATE

Double

Cumulative Incidence Rate

TOTAL_CASES

Integer

Total cumulative cases by area from start

TOTAL_DEATHSInteger

Total cumulative deaths by area from start

NEW_TOTAL_CASESInteger

New total cases for the measurement latest period (day or week)

NEW_TOTAL_DEATHS

Integer

New total deaths compared with the previous period (day or week)

CFR

Double

Case Fatality Ratio (%) Crude

The crude incidence rates (IRs, per 1000 person-years) and incidence rate ratios (IRRs) of transient global amnesia (TGA) after cancer diagnosis, according to sex, calendar period of follow-up, age at follow-up, and previous TGA, a cohort study in Sweden, 2001–2009.

The crude prevalence rate of obesity is defined as the ratio of respondents that are 18 years or older who have a body mass index (BMI) of 30.0 kg/m2 or greater over the total number of respondents in the study (excluding those who refused to answer or those whose information was unknown”). Respondents were excluded if their height was less than 3 ft or equal to/greater than 8 ft; they weighed less than 50 lbs or more than 650 lbs; they had a BMI of less than 12 kg/m2 or 100 kg/m2 and greater; and/or were pregnant.Prevalence data are derived from the Behavioral Risk Factor Surveillance System (BRFSS) 2012.The 500 Cities Project seeks to provide city- and census tract-level small area estimates for chronic disease risk factors, health outcomes, and clinical preventive service use for the largest 500 cities in the United States.Data source: CDC (Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion)Date: 2015

Values between brackets indicate the number of episodes/child-years observation time. Rate ratios are crude estimates of the hazard rate ratios [95%CI] based on a Cox regression model that included multiple episodes per child. A rate ratio

The ratio of MS incidence in different age groups to the baseline age group (10–14 years old) when adjusted for sex and year variables.

SD: standard deviation; CCI: Charlson comorbidity index; IQR: interquartile range; py: person-years; IRR: incidence rate ratio; CI: confidence intervalCrude mortality incidence rate ratios for the dementia and non-dementia group.

Note: 30-day mortality and complications were similar between the peer groups, but failure-to-rescue was less like to occur in the peer groups of major metro- and non-metropolitan (RR = 0.78; 95%CI: 0.60–0.99), district group 1 (RR = 0.57, 95%CI: 0.34–0.94) and district group 2 (RR = 0.61, 95%CI: 0.41–0.90) than that in the peer groups of principal referral and ungrouped acute hospitals.‡P = 0.053;*P≤0.05;§P = (linear 0.02; quadratic 0.007);†P = 0.12.

Crude and adjusted incidence rates (IRs) per 1000 person-years (PY) and 95% confidence intervals (95% CI)), and crude and adjusted rate ratios (RRs) and 95% CI of clinical events/deaths by geographic origin, in heterosexual men and women (Poisson regression, n = 4930, France, 2006–2012).

SD: standard deviation; IQR: interquartile range; py: person-year; IRR: incidence rate ratio; CI: confidence intervalCrude mortality incidence rate ratio among the vascular dementia and non-vascular dementia groups.